Keros Therapeutics, Inc.
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family. Its candidates target pathways involved in the growth, repair and maintenance of tissues including… From the company’s description.
Over the twelve months to Sep 30, 2026, Keros Therapeutics, Inc. reported revenue of $40.76M, down 83.5% from a year earlier, and a net loss of $61.73M. Its operating margin was −179.7%, and operations used $47.85M in cash. In fiscal 2025, it reported revenue of $244.06M, up 6775.0% from fiscal 2024, and net income of $87.01M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Keros Therapeutics, Inc. does
In the company’s own words
Keros Therapeutics, Inc. (Nasdaq: KROS) is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family. Its candidates target pathways involved in the growth, repair and maintenance of tissues including muscle, bone and blood. Rinvatercept (KER-065), designed to inhibit myostatin and activin A, is in development for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Elritercept (KER-050) is being developed for cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and myelofibrosis; Takeda holds an exclusive worldwide license to develop, manufacture and commercialize it outside mainland China, Hong Kong and Macau. Keros also applies its discovery capabilities to potential therapies for neuromuscular and neurodegenerative disorders, rare bone and fibrosis diseases, obesity and frailty. The company reported no commercial products in the provided business description and does not describe reportable revenue segments. Its website is www.kerostx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- LEXINGTON, MA
- Fiscal year end
- December
- CIK
- 1664710
- SIC
- 2834
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Keros Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Keros Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Keros Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Keros Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Keros Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”